MNKD
MannKind Corporation·Healthcare
3.55
0.567%(+0.02)
Close PriceLast Updated: — ET
52W L: $2.2352W H: $6.51
MNKD NEWS
globenewswire.com
14h ago
MannKind to Present at Jefferies Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.
globenewswire.com
21h ago
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS
gurufocus.com
May 12
The $59B Quiet Shift Reshaping How Patients Access Care
The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026
seekingalpha.com
May 7
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
seekingalpha.com
May 7
MannKind: It's Complicated
MannKind Corporation remains a Hold, as revenue growth is increasingly reliant on niche assets like Furoscix and faces margin pressure. United Therapeutics' launch of Tresmi threatens MNKD's Tyvaso DPI royalties, intensifying competitive risks and highlighting MNKD's junior partner status. Pipeline prospects, including MNKD-201 and ralinepag DPI, offer potential but face significant clinical, commercial, and competitive hurdles.
zacks.com
May 6
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
